SciELO - Scientific Electronic Library Online

 
vol.23 número1Algunas consideraciones acerca de la púrpura trombocitopénica trombóticaEfecto in vitro del Ateromixol sobre los linfocitos y neutrófilos humanos índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Cubana de Hematología, Inmunología y Hemoterapia

versión impresa ISSN 0864-0289versión On-line ISSN 1561-2996

Resumen

CASTILLO GONZALEZ, Dunia de la C. HELLP Syndrome: Updating. Rev Cubana Hematol Inmunol Hemoter [online]. 2007, vol.23, n.1. ISSN 0864-0289.

The HELLP syndrome (hemolysis, elevated liver enzymes, low platelet count) belongs to the group of the thrombotic microangiopathies characterized by hemolytic anemia, thrombocytopenia and organ dysfunction. In the HELLP, the elevation of hepatic enzymes is detected as a result of severe hepatocellular damage secondary to the fibrin deposition in the hepatic sinusoids. It appears between 0.5 and 0.9 % of the total of gestations and from 4 to 14 % of all the women that develop preeclampsia/eclampsia. The clinical manifestations vary from general symptoms, such as weakness, fatigue and vomits, to severe forms as loss of vision, and hepatic and intracranial hemorrhage, among others. In most of the patients, the syndrome appears between the 27th and the 37th week of gestation, but it can also be observed in puerperium, from the first moments after delivery up to 7 days later, with a peak of incidence at 48 hours. The maternal mortality associated with this syndrome is 1-24 %, whereas the perinatal is over 40 %, both are closely related to the diagnosis and the maternal and fetal conditions. It is important to make the differential diagnosis with the acute hepatic necrosis of pregnancy. The treatment is aimed at interrupting gestation, preventing convulsions, controlling the arterial hypertension associated with this syndrome, that is observed between 82 and 88 % of the cases, and the associated coagulation disorders. Plasmapheresis, corticosteroids, and liver transplantation, are some of the other therapeutic measures used

Palabras clave : HELLP; hemolytic anemia; thrombocytopenia; hepatic failure; preeclampsia.

        · resumen en Español     · texto en Español

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons